高级别浆液性卵巢癌的个体化治疗。

Personalising Treatment for High-Grade Serous Ovarian Carcinoma.

机构信息

Cambridge University Hospitals, Department of Oncology, Cambridge, UK.

Cambridge University Hospitals, Department of Oncology, Cambridge, UK; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.

出版信息

Clin Oncol (R Coll Radiol). 2018 Aug;30(8):515-524. doi: 10.1016/j.clon.2018.05.008. Epub 2018 Jun 19.

DOI:10.1016/j.clon.2018.05.008

PMID:29934103

Abstract

Ovarian cancer is a heterogeneous group of cancers that differ by cell of origin and genomic features. High-grade serous ovarian cancer (HGSOC) is the commonest histiotype and is characterized by extreme genomic complexity and dysregulation of DNA damage repair pathways, particularly homologous recombination deficiency. New insights from molecular profiling into homologous recombination deficiency now offers the credible possibility of personalizing treatment choices for women with HGSOC using poly(ADP-ribose) polymerase inhibitor (PARP) therapy. Although the presence of tumour infiltrating lymphocytes (TILs) in the microenvironment is associated with improved survival in HGSOC, the role of anti-angiogenic and immune checkpoint inhibitor therapy remains unclear. PARP inhibition combined with immunotherapy is an exciting combination strategy for future therapeutic development for women with advanced HGSOC.

摘要

卵巢癌是一组异质性癌症，其特征在于起源细胞和基因组特征的不同。高级别浆液性卵巢癌（HGSOC）是最常见的组织学类型，其特征是基因组极度复杂，以及 DNA 损伤修复途径，特别是同源重组缺陷的失调。分子谱分析对同源重组缺陷的新见解，现在为使用聚（ADP-核糖）聚合酶抑制剂（PARP）治疗 HGSOC 女性提供了个性化治疗选择的可信可能性。尽管肿瘤浸润淋巴细胞（TILs）在微环境中的存在与 HGSOC 的生存改善相关，但抗血管生成和免疫检查点抑制剂治疗的作用仍不清楚。PARP 抑制联合免疫疗法是为晚期 HGSOC 女性未来治疗发展的一个令人兴奋的联合策略。